Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIO-Lipids: Rimonabant in Obese Patients with Untreated Dyslipidemia
NCT00029835Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2001
- Primary completion
- Nov 2003
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of rimonabant in obesity and dyslipidemia (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in body weight at 1 year. Started Sep 2001; status: completed.
02
Drugs
rimonabant
03
Conditions
obesitydyslipidemia
Beyond the preview
Go deeper on NCT00029835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00029835.